Tuning Reactivity of Platinum(II) Complexes

76 (a)J. Kašpárková, J. Zehnulova, N. Farrell and V. Brabec, J. Biol. Chem., 2001, 276,
22191; (b) M. B. G. Kloster, J. C. Hannis, D. C. Muddiman and N. Farrell,
Biochemistry, 1999, 38, 14731;(c)V. Brabec and J. Kasparova, Drug resist.
Updates, 2005, 8, 131.
77 G. kalayda, S. Komeda, K. Ikeda, T. Sato, M. Chikuma, and J. Reedijk, Eur. J. Inorg.
Chem., 2003, 4347-4355
78 (a) S. van Zutphen, M. Robillard, G. van der Marel, H. Overkleeft, H. den Dulk, J.
Brouwer, and J.Reedijk, Chem. Commun., 2003, 634; (b) J. Zhu, M. Lin, D. Fan, Z.
Wu, Y. Chen, J. Zhang, Y. Lu and Z. Guo, Dalton Trans., 2009, 10889.
79 (a) V. Brabec, J. Kasparkova, O. Vrana, O. Novakova, J. Cox, Y. Qu and N. Farrell,
Biochem., 1995,9, 6781; (b) H. Ertürk, R. Puchta and R. van Eldik, Eur. J. Inorg.
Chem., 2009, 1331.
80 N. Farrell, T. G. Appleton, Y.Qu, J. D. Roberts, A. P. Fontes, K. Skov, P. Wu and Y.
Zou, Biochem., 1995,15480-15486.
81 N. Farrell, Polynuclear platinum drugs. In: Sigel A, Sigel H, editors. Metal ions in
biological systems. New York, Basel: Marcel Dekker, Inc.; 2004, p. 251-96.
82 J. Kasparkova, N. Farrell and V. Brabec, J. Biol. Chem., 2000, 275, 15789.
83 J. Kasparkova, O. Novakova, O. Vrana, N. Farrell, V. Brabec, Biochemistry, 1999,
38, 10997.
84 K. J. Mellish, Y. Qu, N. Scarsdale, N. Farrell, Nucl. Acids Res., 1997, 25, 1265.
85 G. Zhao, H. Lin, S. Zhu, H. Sun and Y. Chen, Anti-Cancer Drug Des., 1998, 13, 769.
86 H. Silva, C. V. Barra, F. V. Rocha, F. Frézard, M. T. P. Lopes and A. P. S. Fontes, J.
Braz. Chem. Soc., 2010, 21, 1961.
87 S. Komeda, H. Ohishi, H. Yamane, M. Harikava, K. Sakaguchi, M. Chikuma, J.Chem.
Soc., Dalton Trans., 1999, 2959-2962.
88 S. Komeda, G. V. Kalayda, M. Lutz, A. L. Spek, Y. Yamanaka, T. Sato, M. Chikuma
and J.Reedijk, J. Med. Chem., 2003, 46, 1210.
89 N. J. Wheate, C. Cullinane, L. K. Webster and J. G. Collins, Anti-Cancer Drug Des.,
2001, 16, 91.
25